Debbie Caswell
LightNews LightNews
banner
caswelldrm.bsky.social
Debbie Caswell
@caswelldrm.bsky.social
70 followers 41 following 13 posts
Principal Research Fellow @UCL | Lung cancer prevention laboratory
Posts Replies Media Videos
caswelldrm.bsky.social
Thank you so much!
September 19, 2025 at 8:49 AM
caswelldrm.bsky.social
Thank you so much!
July 29, 2025 at 11:21 AM
caswelldrm.bsky.social
Thanks so much!
April 9, 2025 at 8:42 AM
caswelldrm.bsky.social
Thank you so much!
April 9, 2025 at 8:42 AM
caswelldrm.bsky.social
Can you please add me as a contributer: www.nature.com/articles/s41...
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance - Nature Genetics
Analyses of in vivo models, cell lines and patient-derived samples show that apolipoprotein B mRNA-editing catalytic subunit 3B (APOBEC3B) not only restrains lung tumor initiation but also that its up...
www.nature.com
April 7, 2025 at 7:12 PM
Reposted by Debbie Caswell
jeffreytownsend.bsky.social
Personalized therapeutic strategies that target APOBEC 🧪 offer promise for the enhancement of TKI treatment efficacy by delaying the evolution of drug resistance in lung cancer.

www.sciencedirect.com/science/arti...
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Genomic instability driven by stress-response-dependent mutagenesis is a key factor in cancer progression. Tyrosine kinase inhibitor therapy, a common…
www.sciencedirect.com
March 23, 2025 at 3:49 PM
Reposted by Debbie Caswell
jeffreytownsend.bsky.social
Our data-driven analysis indicates that inhibition of APOBEC activity would substantially extend therapeutic efficacy 🧪, with the degree of benefit varying based on patient-specific APOBEC mutagenesis levels.

www.sciencedirect.com/science/arti...
APOBEC rate averages versus time gained. This scatter plot illustrates the positive relationship between the average APOBEC rate across sites within patients and the corresponding time gained in each patient. The dashed line is a linear regression trend. This inferred relationship is fairly strong (slope = 1.3) and is statistically significant (P = 0.005) with n = 15 points.
March 23, 2025 at 3:49 PM
Reposted by Debbie Caswell
jeffreytownsend.bsky.social
By analyzing tumor sequence data to infer gene-specific and patient-specific mutation rates, we used (for the first time) some straightforward mathematics of mutation rates to project the delay of resistance obtained by suppression of APOBEC mutation 🧪.

www.sciencedirect.com/science/arti...
Expected time until the first resistance mutation without complete suppression of APOBEC (purple bars) and with complete suppression of APOBEC (black bars) in each patient, expressed in molecular clock units, and the consequent expected percentage of time that could have been gained before resistance arose with APOBEC inhibited. Resistance-associated variants were identified by Caswell et al. and Isozaki et al. in each patient
March 23, 2025 at 3:49 PM
Reposted by Debbie Caswell
jeffreytownsend.bsky.social
@alkpositiveuk.bsky.social—ALK resistance mutations show greater APOBEC attribution than e.g. EGFR mutations. Therefore, patients with ALK+ tumors would benefit more from therapies suppressing APOBEC activity 🧪.

www.sciencedirect.com/science/arti...
Mutational signature weights (potential mutational processes) underlying TKI resistance-associated gene variants in non-small-cell lung cancer patient samples, sorted by descending attribution to A3A/A3B processes.
March 23, 2025 at 3:49 PM
Reposted by Debbie Caswell
jeffreytownsend.bsky.social
We estimated the contribution of APOBEC to mutational signatures in the twenty-one NSCLC patients that featured detailed clinical records of TKI treatment 🧪 and tissue sampling during or after treatment or at autopsy.

www.sciencedirect.com/science/arti...
Mutational signature weights (potential mutational processes) underlying TKI resistance-associated gene variants in non-small-cell lung cancer patient samples, sorted by descending attribution to A3A/A3B processes.
March 23, 2025 at 3:49 PM